Furthermore, in the studies of Hyojin et al, the results also suggested vimentin did not correlate with DFS in lung adenocarcinoma, and Alex et al. reported that vimentin did not predict progression-free survival (PFS)[58]. Here, VIM is linked to lung adenocarcinoma.